Differentially expressed genes in CD38+ vs CD38− B-CLL patients
| Accession no. . | Gene description . | UPN 1-38 . | UPN 39-77 . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Median CD38− . | Median CD38+ . | Ratio CD38+/CD38− . | P . | Median CD38− . | Median CD38+ . | Ratio CD38+/CD38− . | P . | ||
| D84276 | CD38 | 79 | 212 | 2.7 | .0215 | 67 | 185 | 2.8 | .0111 |
| D87119 | Osteoblast protein | 393 | 702 | 1.8 | .0215 | 406 | 973 | 2.4 | .0047 |
| L29219 | CDC-like kinase | 1501 | 939 | 0.6 | .0183 | 1662 | 997 | 0.6 | .0296 |
| J04027 | ATPase | 2961 | 1766 | 0.6 | .0251 | 3313 | 1807 | 0.5 | .0098 |
| L05148 | ZAP-70 kinase | 1339 | 3177 | 2.4 | .0001 | 1594 | 3032 | 1.9 | .0328 |
| L08895 | MEF2C | 1803 | 875 | 0.5 | .0023 | 1039 | 589 | 0.6 | .0194 |
| M62302 | GDF-1 | 128 | 243 | 1.9 | .0423 | 66 | 139 | 2.1 | .0296 |
| M62994 | Thyroid autoantigen | 757 | 1270 | 1.7 | .0423 | 698 | 1351 | 1.9 | .0111 |
| M97963 | ISGF-3 | 995 | 1544 | 1.6 | .0183 | 2159 | 4201 | 1.9 | .0267 |
| S626696 | CD21 | 138 | 258 | 1.9 | .0366 | 189 | 425 | 2.2 | .0296 |
| X16983 | Integrin α4, CD49d | 186 | 384 | 2.1 | .0023 | 215 | 361 | 1.7 | .0174 |
| X63741 | Pilot mRNA | 278 | 77 | 0.3 | .0050 | 252 | 49 | 0.2 | .0019 |
| X84373 | RIP140 | 496 | 176 | 0.4 | .0102 | 393 | 111 | 0.3 | .0139 |
| X89986 | Apoptotic inducer | 99 | 251 | 2.5 | .0232 | 125 | 375 | 3.0 | .0098 |
| Accession no. . | Gene description . | UPN 1-38 . | UPN 39-77 . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Median CD38− . | Median CD38+ . | Ratio CD38+/CD38− . | P . | Median CD38− . | Median CD38+ . | Ratio CD38+/CD38− . | P . | ||
| D84276 | CD38 | 79 | 212 | 2.7 | .0215 | 67 | 185 | 2.8 | .0111 |
| D87119 | Osteoblast protein | 393 | 702 | 1.8 | .0215 | 406 | 973 | 2.4 | .0047 |
| L29219 | CDC-like kinase | 1501 | 939 | 0.6 | .0183 | 1662 | 997 | 0.6 | .0296 |
| J04027 | ATPase | 2961 | 1766 | 0.6 | .0251 | 3313 | 1807 | 0.5 | .0098 |
| L05148 | ZAP-70 kinase | 1339 | 3177 | 2.4 | .0001 | 1594 | 3032 | 1.9 | .0328 |
| L08895 | MEF2C | 1803 | 875 | 0.5 | .0023 | 1039 | 589 | 0.6 | .0194 |
| M62302 | GDF-1 | 128 | 243 | 1.9 | .0423 | 66 | 139 | 2.1 | .0296 |
| M62994 | Thyroid autoantigen | 757 | 1270 | 1.7 | .0423 | 698 | 1351 | 1.9 | .0111 |
| M97963 | ISGF-3 | 995 | 1544 | 1.6 | .0183 | 2159 | 4201 | 1.9 | .0267 |
| S626696 | CD21 | 138 | 258 | 1.9 | .0366 | 189 | 425 | 2.2 | .0296 |
| X16983 | Integrin α4, CD49d | 186 | 384 | 2.1 | .0023 | 215 | 361 | 1.7 | .0174 |
| X63741 | Pilot mRNA | 278 | 77 | 0.3 | .0050 | 252 | 49 | 0.2 | .0019 |
| X84373 | RIP140 | 496 | 176 | 0.4 | .0102 | 393 | 111 | 0.3 | .0139 |
| X89986 | Apoptotic inducer | 99 | 251 | 2.5 | .0232 | 125 | 375 | 3.0 | .0098 |
For comparative analysis of CD38+ and CD38− B-CLL patients, only genes called present by the Affymetrix algorithm in at least one third of the profiles were selected (approximately 2500 in both series). Differentially regulated genes were identified by comparing the median signal intensities of the two groups using the Wilcoxon rank sum test at a significance level of .05 and defining a cut-off fold change of ± 1.5 (approximately 75 genes in each series [UPNs 1-38 and UPNs 39-77, respectively]). Fourteen of these CD38 distinction candidate genes were found to fulfill the statistical selection criteria in both series and are shown in the table. Data are median signal intensities of the two groups.